Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose LTI-291 in healthy middle-aged and older volunteers
NL-OMON44195Active, not recruiting
- Sponsor
- Lysosomal Therapeutics
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of pariceract in GBA1-associated Parkinson's disease (GBA-PD) (2 arms), sponsored by Lysosomal Therapeutics. Primary endpoints: Safety and tolerability endpoints, Pharmacokinetic endpoints and 1 more. Started Oct 2017; status: active, not recruiting.
02
Drugs
pariceract
03
Conditions
GBA1-associated Parkinson's disease (GBA-PD)
Beyond the preview
Go deeper on NL-OMON44195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44195.